Santini, V., Komrokji, R., Savona, M., Diez-Campelo, M., Fenaux, P., Sekeres, M., Madanat, Y., Valcárcel, D., Jonasova, A., Belohlavkova, P., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F., Feller, F., Navada, S., Zeidan, A., Platzbecker, U. (2025). Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS). Blood. https://doi.org/10.1182/blood-2025-2074